In addition, from the available evidence, the anti-inflammatory activity of GCK in the treatment of RA is not as favorable as that of other active ingredients, and it mainly exerts part of its effect through immune modulation, which means that GCK may not be able to produce better efficacy in middle- and late-stage RA. The gene discussed is GCK; the disease is rheumatoid arthritis.